Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Celgene Corporation
Femme et Homme Max 99 ans
Celgene Corporation
MAJ Il y a 5 ans
An open-label study for the safety and efficacy of pomalidomide in refractory or refractory/relapsed multiple myeloma subjects
To evaluate the efficacy of pomalidomide (CC-4047) monotherapy in subjects with refractory or relapsed and refractory multiple myeloma who discontinued from Treatment Arm B (dexamethasone alone) of St...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Celgene Corporation
MAJ Il y a 5 ans
ESTUDIO EN FASE 2, MULTICÉNTRICO, ALEATORIZADO, DOBLE CIEGO Y DE GRUPOS PARALELOS PARA EVALUAR LA SEGURIDAD Y LA EFICACIA DE DIFERENTES REGÍMENES DE DOSIS DE LENALIDOMIDA (REVLIMID®) EN SUJETOS CON LEUCEMIA LINFOCÍTICA CRÓNICA DE CÉLULAS B RESISTENTE O EN RECAÍDA. (A PHASE 2, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP STUDY OF THE SAFETY AND EFFICACY OF DIFFERENT LENALIDOMIDE (REVLIMID®) DOSE REGIMENS IN SUBJECTS WITH RELAPSED OR REFRACTORY B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA)
Evaluar la seguridad de diferentes regímenes de dosis de lenalidomida en sujetos con LLC de células B resistente o en recaída. (To evaluate the safety of different lenalidomide dose regimens in subjec...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Celgene Corporation
MAJ Il y a 5 ans
Phase 3 study to evaluate safety and effectiveness of oral Apremilast (CC-10004) in patients with Psoriatic Arthritis and a psoriasis lesion
The primary objective of the study is to evaluate the clinical efficacy of 2 doses of apremilast (20 mg or 30 mg orally BID), compared with placebo, on the signs and symptoms of psoriatic arthritis (P...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Celgene Corporation
MAJ Il y a 5 ans
A PHASE 2, OPEN-LABEL STUDY TO ASSESS THE EFFICACY AND SAFETY OF LENALIDOMIDE IN COMBINATION WITH CETUXIMAB IN PRETREATED SUBJECTS WITH KRAS MUTANT METASTATIC COLORECTAL CANCER
•Phase 2a To determine the Maximal Tolerated Dose (MTD) of lenalidomide in combination with cetuximab in subjects with KRAS mutant metastatic CRC. •Phase 2b To determine the response rate in subjec...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Celgene Corporation
MAJ Il y a 5 ans
Study To Compare The Benefit And Safety Of Luspatercept (ACE-536) Versus Placebo in subjects with lack of normal Red Blood Cells Requiring Transfusion due to myelodysplastic syndromes (MDS) with ring sideroblasts
To evaluate RBC transfusion independence (RBC-TI) of luspatercept compared with placebo for the treatment of anemia due to IPSS-R very low, low, or intermediate risk MDS in subjects with ring siderobl...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Celgene Corporation
MAJ Il y a 5 ans
Safety study of oral azacitidine (CC-486) in patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes experiencing no symptom of the disease after stem cell transplantation
To determine the maximal tolerated dose (MTD) of oral azacitidine in subjects with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) after allogeneic hematopoietic stem cell transplantat...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Celgene Corporation
MAJ Il y a 5 ans
A Phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy and safety study of two dose regimens of CC-10004 in subjects with active psoriatic arthritis
To evaluate the 84-day clinical efficacy of 2 dose regimens of CC-10004 (20 mg per os [PO] twice per day [BID, total daily dose of 40 mg] or 40 mg PO once per day [QD], subsequent to a 7-day dose titr...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Celgene Corporation
MAJ Il y a 5 ans
A study to evaluate the efficacy and safety of Apremilast, Etanercept and placebo, in subjects with moderate to severe plaque psoriasis
To evaluate the clinical efficacy and safety of oral apremilast 30 mg twice a day (BID) compared with placebo, in subjects with moderate to severe plaque psoriasis at Week 16
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Celgene Corporation
MAJ Il y a 5 ans
A study of sotatercept given by injection for evaluating the safety, pharmacokinetics (effect of body on drug), and effect on anemia and bone disorder in people with end stage kidney disease on hemodialysis that are switched from erythropoiesis stimulating agents (medication to treat anemia) to sotatercept
Part 1 To determine the multiple dose pharmacokinetics, safety, and tolerability of IV and SQ dosing of sotatercept administered at each dose level. Part 2 To determine the safety and efficacy of t...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Celgene Corporation
MAJ Il y a 5 ans
TRIAL OF ABRAXANE AND GEMCITABINE TO TREATMENT PANCREATIC CANCER PATIENTS WHO CAN NOT HAVE SURGERY BECAUSE OF CANCER LOCATION ENSAYO DE ABRAXANE Y GEMCITABINA PARA EL TRATAMIENTO DE PACIENTES CON CÁNCER DE PÁNCREAS QUE NO PUEDEN SOMETERSE A CIRUGÍA DEBIDO A LA LOCALIZACIÓN DEL CÁNCER
To evaluate the time to treatment failure in LAPC subjects treated with nab-paclitaxel plus gemcitabine as induction therapy followed by Investigator?s Choice of treatment Evaluar el tiempo tran...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Précédent
1
2
3
4
5
6
Suivant